Ardent Health Partners, Inc. (ARDT) AI Stock Analysis

Ardent Health, Inc. owns and operates a network of hospitals and clinics providing healthcare services throughout the United States. Its offerings span general and specialty care, including internal medicine, general surgery, cardiology, oncology, orthopedics, women's services, neurology, urology, and emergency services in inpatient and ambulatory care settings. In addition, the company operates acute care hospitals, including rehabilitation and surgical hospitals. It also maintains ambulatory facilities and telehealth services such as primary and specialty care clinics, ambulatory surgery centers, urgent care centers, free-standing emergency departments, and diagnostic imaging centers.

Revenue grew from $4.87B in FY2021 to $5.13B in FY2022, $5.41B in FY2023, $5.97B in FY2024, and reached $6.32B in FY2025, delivering an 8.7% 5-year revenue CAGR from FY2018 to FY2025. Operating margins fluctuated across this period, starting at 9.0% in FY2021, moving to 4.2% in FY2022 and FY2023, rising to 6.8% in FY2024, and recording 5.1% in FY2025. Net income stood at $135.8M in FY2025, resulting in a net margin of 2.1% and diluted EPS of $1.93. For the trailing twelve months, revenue reached $6.41B with an operating margin of 3.4%. For the latest quarter ended June 30, 2026, quarterly revenue fell 1.4% and quarterly earnings declined 77.1% year-over-year.

As of June 30, 2026, the company held $724.5M in cash and short-term investments against total debt of $2.27B, resulting in net debt of $1.54B. Shareholders' equity was $1.35B and total assets were $5.28B, yielding a debt-to-equity ratio of 1.68 and a current ratio of 2.10. Operating cash flow expanded to $470.5M in FY2025, supporting capital expenditures of $211.9M and resulting in free cash flow of $258.6M.

Ardent Health trades at a trailing P/E of 22.1x and a forward P/E of 9.5x, compared to medians of 24.6x and 17.3x, respectively, for its US-listed Healthcare peers. Its EV to EBITDA multiple sits at 7.2x versus the peer median of 12.0x, while its price-to-sales multiple is 0.3x compared to 4.1x for peers. Over the past year, the stock returned -18.1%, trailing the S&P 500 (SPY) return of 16.8%. Year to date, however, ARDT has gained 35.3%.

Wall Street coverage consists of 6 Strong Buy, 1 Buy, 5 Hold, and 1 Sell ratings. The mean price target of $12.67 indicates a 6.0% upside compared to the last close of $11.95 on October 16, 2026. For the current fiscal year ending December 31, 2026, analysts expect revenue of $6.46B and EPS of $1.09, which represents an EPS decline of 29.6%. The company has beaten EPS expectations in 3 of the last 4 quarters, and its next earnings date is November 11, 2026.

This page is an AI-written research summary of Ardent Health Partners, Inc. (ARDT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ARDT income statement, ARDT balance sheet, ARDT key metrics, ARDT analyst forecast, ARDT chart. See the ARDT stock overview for the latest quote and news.